[
  {
    "ts": "2025-11-11T06:02:23+00:00",
    "headline": "Novo Nordisk Shares Pop After Stepping Back From Metsera Chase",
    "summary": "Novo Nordisk Climbs After Dropping Out of Bidding War for Metsera",
    "url": "https://finance.yahoo.com/news/nvo-novo-nordisk-climbs-dropping-162954873.html",
    "source": "GuruFocus.com",
    "provider": "yfinance",
    "raw": {
      "id": "322bdb23-0393-3487-8216-f65115922064",
      "content": {
        "id": "322bdb23-0393-3487-8216-f65115922064",
        "contentType": "STORY",
        "title": "Novo Nordisk Shares Pop After Stepping Back From Metsera Chase",
        "description": "",
        "summary": "Novo Nordisk Climbs After Dropping Out of Bidding War for Metsera",
        "pubDate": "2025-11-11T06:02:23Z",
        "displayTime": "2025-11-11T06:02:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57",
          "originalWidth": 400,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9TzR39bxuUCR99sbuZJDMQ--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 400,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NjQrAqlrjUwsW.v1rUBg.Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/us.finance.gurufocus/7e63317195f3cefdce4c30843a9d7c57.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GuruFocus.com",
          "url": "http://www.gurufocus.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/nvo-novo-nordisk-climbs-dropping-162954873.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/nvo-novo-nordisk-climbs-dropping-162954873.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T09:10:00+00:00",
    "headline": "Why a Strong Quarter Wasn't Enough to Send Shares of Pfizer Soaring",
    "summary": "Pfizer not only beat expectations last quarter, but also boosted its guidance.",
    "url": "https://www.fool.com/investing/2025/11/11/why-strong-quarter-not-enough-help-pfizer-stock/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "df87726b-d863-3569-a85c-1b65b82bebd0",
      "content": {
        "id": "df87726b-d863-3569-a85c-1b65b82bebd0",
        "contentType": "STORY",
        "title": "Why a Strong Quarter Wasn't Enough to Send Shares of Pfizer Soaring",
        "description": "",
        "summary": "Pfizer not only beat expectations last quarter, but also boosted its guidance.",
        "pubDate": "2025-11-11T09:10:00Z",
        "displayTime": "2025-11-11T09:10:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/6be3e5f958c64218c0a9ce7df9143685",
          "originalWidth": 1400,
          "originalHeight": 901,
          "caption": "Worried investor looking at a computer.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vxcfke3UkT5oZoxPjblFWw--~B/aD05MDE7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/6be3e5f958c64218c0a9ce7df9143685.cf.webp",
              "width": 1400,
              "height": 901,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/mk374tL_Y547TPH7KgNG7g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/6be3e5f958c64218c0a9ce7df9143685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/11/why-strong-quarter-not-enough-help-pfizer-stock/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/why-strong-quarter-wasnt-enough-091000122.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T10:29:00+00:00",
    "headline": "Vaccines Market Research and Forecast Report 2025-2030: Growing Focus on Vaccine Development, New Product Launches, and Large-scale Immunization Programs Continues to Accelerate Growth",
    "summary": "The global vaccines market is projected to grow from USD 50.46 billion in 2025 to USD 63.66 billion by 2030, achieving a CAGR of 4.8%. Key drivers include high rates of infectious diseases, technological innovations, and robust government support. The pneumococcal and multivalent vaccine segments dominate due to rising pneumococcal infections and demand for comprehensive immunization, respectively. The Asia Pacific region is the fastest-growing market, driven by increased public health initiativ",
    "url": "https://finance.yahoo.com/news/vaccines-market-research-forecast-report-102900281.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "3b346255-9981-3397-8c0e-bd5f46227b0a",
      "content": {
        "id": "3b346255-9981-3397-8c0e-bd5f46227b0a",
        "contentType": "STORY",
        "title": "Vaccines Market Research and Forecast Report 2025-2030: Growing Focus on Vaccine Development, New Product Launches, and Large-scale Immunization Programs Continues to Accelerate Growth",
        "description": "",
        "summary": "The global vaccines market is projected to grow from USD 50.46 billion in 2025 to USD 63.66 billion by 2030, achieving a CAGR of 4.8%. Key drivers include high rates of infectious diseases, technological innovations, and robust government support. The pneumococcal and multivalent vaccine segments dominate due to rising pneumococcal infections and demand for comprehensive immunization, respectively. The Asia Pacific region is the fastest-growing market, driven by increased public health initiativ",
        "pubDate": "2025-11-11T10:29:00Z",
        "displayTime": "2025-11-11T10:29:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/fc91206bda6644828a12637239d6fd19",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Global Vaccines Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BavSj1vVI4feW91iO1txhA--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/fc91206bda6644828a12637239d6fd19.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5nbRkDYK9HhpgcIHbJSVqg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/fc91206bda6644828a12637239d6fd19.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vaccines-market-research-forecast-report-102900281.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vaccines-market-research-forecast-report-102900281.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "SAN.PA"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T09:25:00+00:00",
    "headline": "Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?",
    "summary": "Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.",
    "url": "https://www.fool.com/investing/2025/11/11/win-intense-battle-rule-glp-1-drug-lly-nvo-pfe/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "7600dc29-a7f0-397a-8c3c-7b2508f19c52",
      "content": {
        "id": "7600dc29-a7f0-397a-8c3c-7b2508f19c52",
        "contentType": "STORY",
        "title": "Who's Winning the Intense Battle to Rule the White-Hot GLP-1 Drug Market?",
        "description": "",
        "summary": "Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.",
        "pubDate": "2025-11-11T09:25:00Z",
        "displayTime": "2025-11-11T09:25:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/0f189b86e73e67f4cf765d58dbf57476",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A package of a weight-loss drug next to a barbell.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uy.JmKH8mGx7AIwWfdl7XA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/0f189b86e73e67f4cf765d58dbf57476.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A1zrw5Cb3qAMPzn97Rm55w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/0f189b86e73e67f4cf765d58dbf57476.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/11/win-intense-battle-rule-glp-1-drug-lly-nvo-pfe/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/whos-winning-intense-battle-rule-092500402.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T10:58:40+00:00",
    "headline": "Pfizer's (NYSE:PFE) Solid Earnings Are Supported By Other Strong Factors",
    "summary": "Pfizer Inc. ( NYSE:PFE ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...",
    "url": "https://finance.yahoo.com/news/pfizers-nyse-pfe-solid-earnings-105840489.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b8b932bf-8c7e-37c1-91e3-fa2378b2830e",
      "content": {
        "id": "b8b932bf-8c7e-37c1-91e3-fa2378b2830e",
        "contentType": "STORY",
        "title": "Pfizer's (NYSE:PFE) Solid Earnings Are Supported By Other Strong Factors",
        "description": "",
        "summary": "Pfizer Inc. ( NYSE:PFE ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...",
        "pubDate": "2025-11-11T10:58:40Z",
        "displayTime": "2025-11-11T10:58:40Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizers-nyse-pfe-solid-earnings-105840489.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizers-nyse-pfe-solid-earnings-105840489.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T10:30:00+00:00",
    "headline": "Obesity Drugs Are About to Go Mass-Market",
    "summary": "For most of Big Pharma, drug discounts have largely been about damage control.  After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief.  For  Eli Lilly’s    David Ricks  and  Novo Nordisk’s    Mike Doustdar,  who paid their own visit to the White House last week, the calculus is different.",
    "url": "https://www.wsj.com/health/pharma/ozempic-glp1-weight-loss-mass-market-f70f8484?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "b2aa9d81-f8af-30ce-a574-a07b350656b9",
      "content": {
        "id": "b2aa9d81-f8af-30ce-a574-a07b350656b9",
        "contentType": "STORY",
        "title": "Obesity Drugs Are About to Go Mass-Market",
        "description": "",
        "summary": "For most of Big Pharma, drug discounts have largely been about damage control.  After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief.  For  Eli Lilly’s    David Ricks  and  Novo Nordisk’s    Mike Doustdar,  who paid their own visit to the White House last week, the calculus is different.",
        "pubDate": "2025-11-11T10:30:00Z",
        "displayTime": "2025-11-11T10:30:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/b2aa9d81-f8af-30ce-a574-a07b350656b9/obesity-drugs-are-about-to-go.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/d9fbb83aa02eec1c9b51828685ea6e31",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/r3EYtfWi7DUenDdrNOIVjQ--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/d9fbb83aa02eec1c9b51828685ea6e31.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/T5qoowdQPCQB7Wmdu4lvWA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/d9fbb83aa02eec1c9b51828685ea6e31.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/ozempic-glp1-weight-loss-mass-market-f70f8484?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T05:36:17+00:00",
    "headline": "The Top 5 Analyst Questions From Pfizer’s Q3 Earnings Call",
    "summary": "Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth in non-COVID products and disciplined cost management as key drivers of performance. CEO Albert Bourla emphasized the company’s ability to deliver adjusted earnings above expectations, noting, “Our business is performing well, and we are raising the range of our adjusted diluted EPS guidance for full year 2025.” The quarter saw operational declines in legacy COVID-19 prod",
    "url": "https://finance.yahoo.com/news/top-5-analyst-questions-pfizer-053617246.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "bdba5846-a743-3f1a-946c-46893bfc5870",
      "content": {
        "id": "bdba5846-a743-3f1a-946c-46893bfc5870",
        "contentType": "STORY",
        "title": "The Top 5 Analyst Questions From Pfizer’s Q3 Earnings Call",
        "description": "",
        "summary": "Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth in non-COVID products and disciplined cost management as key drivers of performance. CEO Albert Bourla emphasized the company’s ability to deliver adjusted earnings above expectations, noting, “Our business is performing well, and we are raising the range of our adjusted diluted EPS guidance for full year 2025.” The quarter saw operational declines in legacy COVID-19 prod",
        "pubDate": "2025-11-11T05:36:17Z",
        "displayTime": "2025-11-11T05:36:17Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "PFE Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o3tZoPUio75qXATbHoc_Hg--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/o5rZqD7vIoFGnsFYAS_Ztw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/1ff5bd386bd84b91b34108fd5f310eca.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-5-analyst-questions-pfizer-053617246.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-5-analyst-questions-pfizer-053617246.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-11T14:40:00+00:00",
    "headline": "Sickle Cell Disease Treatment Market Research Report 2025 Featuring Novartis, Pfizer, Bluebird Bio, GlycoMimetics, Emmaus Medical, BMS, CRISPR Therapeutics, Graphite Bio",
    "summary": "The Sickle Cell Disease Treatment Market offers significant opportunities with advancements in gene editing, stem cell therapies, and precision medicine driving innovation. Increased awareness and advocacy have spurred global initiatives for better diagnosis, research funding, and equitable access, addressing unmet needs and fostering partnerships. Sickle Cell Disease Treatment Market Sickle Cell Disease Treatment Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The \"Sickle Cell Disease Treatmen",
    "url": "https://finance.yahoo.com/news/sickle-cell-disease-treatment-market-144000751.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "63842d53-2f72-3f27-a405-f0e1b3c1c855",
      "content": {
        "id": "63842d53-2f72-3f27-a405-f0e1b3c1c855",
        "contentType": "STORY",
        "title": "Sickle Cell Disease Treatment Market Research Report 2025 Featuring Novartis, Pfizer, Bluebird Bio, GlycoMimetics, Emmaus Medical, BMS, CRISPR Therapeutics, Graphite Bio",
        "description": "",
        "summary": "The Sickle Cell Disease Treatment Market offers significant opportunities with advancements in gene editing, stem cell therapies, and precision medicine driving innovation. Increased awareness and advocacy have spurred global initiatives for better diagnosis, research funding, and equitable access, addressing unmet needs and fostering partnerships. Sickle Cell Disease Treatment Market Sickle Cell Disease Treatment Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The \"Sickle Cell Disease Treatmen",
        "pubDate": "2025-11-11T14:40:00Z",
        "displayTime": "2025-11-11T14:40:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/3c0198f65e137ab2870336e6d2f046d7",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Sickle Cell Disease Treatment Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/A650IVt5yWEQA1T.pBq0kQ--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3c0198f65e137ab2870336e6d2f046d7.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/vhZZgQ1pbmMzd8AEZIqPFg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/3c0198f65e137ab2870336e6d2f046d7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sickle-cell-disease-treatment-market-144000751.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sickle-cell-disease-treatment-market-144000751.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BLUE"
            },
            {
              "symbol": "CBIO"
            },
            {
              "symbol": "CRSP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]